Otsuka Pharmaceutical Co. Ltd.'s deal with H. Lundbeck A/S gives the Japanese pharma a piece of the most advanced serotonin (5-HT6) receptor antagonist to treat the cognitive symptoms of Alzheimer's disease. The partners expect to start a Phase III trial of the molecule - Lu AE58054 - this year.

The March deal is part of a 2011 neurology alliance between Lundbeck and Otsuka to co-develop and co-commercialize up to five products. Lu AE58054 is the first Lundbeck compound and the third compound overall to be included (see BioCentury, Dec. 5, 2011).